Clinical trials: Class I Obesity
Overweight, Obesity
Effect of Chili Pepper Extract on Weight and Fat Loss and Metabolism Increase
The purpose of this study is to test the safety and effectiveness of a purified extract of CH-19 Sweet, containing capsinoids.
- Trial name
- NCT00825838
- Testing
- Chronic consumption of chili pepper extract
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ajinomoto USA, INC.
Overweight, Prediabetic State
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and…
- Conditions
- Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
- Trial name
- ATTAIN-NOW (NCT07794579)
- Testing
- Orforglipron
- Where
- 180 sites in United States, Argentina and 10 more
- Volunteers
- 2,001 people
- Sponsor
- Eli Lilly and Company
Obesity
Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss
Multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight. One of the most studied pathways involves the melanocortin receptor.
- Trial name
- NCT00779519
- Testing
- TTP435
- Where
- 12 sites in United States, Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- vTv Therapeutics
Obesity
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers.
- Trial name
- NCT06804603
- Testing
- Tradipitant
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Vanda Pharmaceuticals
Overweight and Obesity
Safety and Feasibility Assessment of the Bio-electrical One Day Capsule System in Overweight and Class I Obese Participants
The study represents the first effort to prospectively investigate the Melcap's bio-electrical ingestible ODC system in human. The study goal is to evaluate the safety and feasibility of GES treatment in stomach and in the small…
- Trial name
- NCT03734081
- Testing
- ODC system (type 1 capsule), ODC system (type 2 capsule)
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Melcap Systems Ltd.